What does Noile-Immune Biotech Inc. do?
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology…
What is Noile-Immune Biotech Inc.'s P/E and P/B ratio?
Noile-Immune Biotech Inc. has a P/E ratio of -5.1 and a P/B ratio of 1.07.
What is Noile-Immune Biotech Inc.'s debt-to-equity ratio?
Noile-Immune Biotech Inc. has a debt-to-equity ratio of 0.00.
How much does Noile-Immune Biotech Inc. owe compared with what it owns?
Noile-Immune Biotech Inc. owes ¥0.02 for every ¥1 it owns (balance sheet Jun 2026), which is low.
What is Noile-Immune Biotech Inc.'s Positivity rank?
Noile-Immune Biotech Inc. is ranked #2,031 of 10,750 companies globally and #845 of 3,683 in Japan on PositoAI, with a Positivity Score of 23,298.
Does Noile-Immune Biotech Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for Noile-Immune Biotech Inc..
Where can I read the latest news about Noile-Immune Biotech Inc.?
Recent headlines about Noile-Immune Biotech Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Noile-Immune Biotech Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Noile-Immune Biotech Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.